Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Biogen IncTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Schwab US Dividend Equity ETF — how do they compare? Biogen Inc trades at $206.54 (market cap $30.13B), while Schwab US Dividend Equity ETF trades at $34.19. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.

BIIBSCHD
Market Cap
$30.13B
Sector
HealthBroad Market / Factor
52-Week High
$216.63$34.27
52-Week Low
$128.93$26.44
Enterprise Value
$37.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

Schwab US Dividend Equity ETF

SCHD trades at $34.11, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is a core holding for dividend investors, highlighted by a recent $0.25 dividend declaration for June 2026. Media coverage emphasizes its role in retirement income strategies, though some articles note performance gaps versus peers like VYM.

Outlook remains stable for income-focused investors, with SCHD offering reliable dividends amid market rotations. Risks include interest rate sensitivity and tax inefficiencies in taxable accounts. Institutional interest persists, as seen in Barry Investment Advisors' 29.9% stake increase in Q2 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD